1 Xing L.

Dai Z.

Jabbari A.

et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

2 Liu L.Y.

Craiglow B.G.

Dai F.

King B.A. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients.

3 Kennedy Crispin M.

Ko J.M.

Craiglow B.G.

et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.

4 Mackay-Wiggan J.

Jabbari A.

Nguyen N.

et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

5 Vandiver A.

Girardi N.

Alhariri J.

Garza L.A. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.

4 Mackay-Wiggan J.

Jabbari A.

Nguyen N.

et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

To the Editor: Recent advances in our understanding of the pathogenesis of alopecia areata (AA)have led to the use of Janus kinase (JAK) inhibitors for the treatment of AA.There are considerably more data regarding the JAK1/3 inhibitor tofacitinib for treatment of AA than the JAK1/2 inhibitor ruxolitinib.In an open-label study of 12 patients with moderate-to-severe AA, high-dose ruxolitinib was efficacious.We present a series of 8 patients with severe AA treated with ruxolitinib and show that hair regrowth may be achieved at a lower dose.